16 December 2019 - The National Institute for Health and Care Excellence has given its stamp of approval for NHS use of Vifor Pharma’s hyperkalaemia drug Veltassa (patiromer).

The drug, which was initially turned down by the cost regulator in 2018, will be offered as an option for adults in emergency care or for people with chronic hyperkalaemia and may benefit 13,600 people.

Veltassa was previously not recommended due to a lack of clinical and cost-effectiveness data, however, following new evidence and a lower price, it is now considered an “acceptable use of NHS resources”, the Institute noted.

Read Pharma Times article